If constipation persists despite lifestyle measures, discussing appropriate laxative options with a pharmacist or GP is advisable
Pharmaceutical investments in liraglutide formulation optimization and delivery enhancement continue to strengthen adoption among healthcare providers
Discuss the relapse with your prescriber to adjust your cessation plan, potentially adding varenicline or NRT if tirzepatide alone isnt sufficient
Rebuilding that muscle becomes one of the most effective ways to support your metabolism as your appetite returns
BPC-157 (Body Protection Compound-157) is a synthetic peptide sequence derived from a protective protein found naturally in gastric juice
NICE technology appraisal TA875 (semaglutide 2.4 mg, Wegovy) recommends semaglutide as an option for managing overweight and obesity in adults when all of the following criteria are met: [2] [3] BMI of at least 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, obstructive sleep apnoea, or cardiovascular disease), or a BMI of 3034.9 kg/m in specific circumstances defined within the appraisal (for example, recent-onset type 2 diabetes) Treatment is delivered as part of a specialist multidisciplinary weight management service (Tier 3 or equivalent) Use is recommended for a maximum of two years under current NHS commissioning arrangements NICE technology appraisal TA1026 addresses tirzepatide (Mounjaro) for weight management, recommending it for adults with a BMI of 35 kg/m or above alongside at least one weight-related comorbidity, again within a specialist service context
